In 2021, there were 11.96 million new stroke cases worldwide, with ischemic stroke (IS) accounting for 65.3%. China has an ...
DEEPER REVEAL clinical trial (NCT05358353) 12-month results evaluating the Spur Stent were presented at the SIR 2026 Annual ...
Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, ...
The NPPA has revised ceiling prices for coronary stents to make life-saving devices more affordable. Hospitals must follow ...
Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has applied for CE Mark approval for its ...
Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients’ activity and quality of life. Endovascular therapy can ...
Endospan, a privately-held company pioneering solutions for the endovascular repair of aortic arch disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the NEXUS (R) ...
LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group"; stock code: ...
Endospan, an Israel-based developer of solutions for the endovascular repair of aortic arch disease, announced that the FDA ...
InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana(R) Thrombectomy ...
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 ...
Artivion announces Endospan’s NEXUS Aortic Arch System receives US FDA approval: Atlanta Wednesday, April 8, 2026, 14:00 Hrs [IST] Artivion, Inc., a leading cardiac and vascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results